GlassScriptPhysician profile
Amer A Khan
NPI 1487652855
$10,239.93
in general payments reported to CMS, 2019-2025
37 companies · $2,394 in 2025
The $2,394 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,475 · 2020: $510 · 2021: $1,487 · 2022: $1,527 · 2023: $1,195 · 2024: $1,652 · 2025: $2,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,132 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,132.36 |
| Education | $108.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,174.97 | 2019-2023 | Krystexxa |
| Vifor Pharma, INC. | $927.89 | 2019-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $917.52 | 2021-2025 | |
| Amgen INC. | $845.59 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $746.33 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $582.75 | 2020-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $577.00 | 2019-2025 | Farxiga, Lokelma |
| Aurinia Pharma U.S., INC. | $400.31 | 2021-2025 | Lupkynis |
| Travere Therapeutics, INC. | $371.80 | 2022-2025 | Filspari |
| Fresenius USA Marketing, INC. | $371.35 | 2019-2025 | Velphoro, Velphoro |
| Calliditas Therapeutics US INC. | $346.46 | 2023-2025 | Tarpeyo |
| Ardelyx, INC. | $322.06 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Ani Pharmaceuticals, INC. | $309.17 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $302.97 | 2019 | |
| Opko Pharmaceuticals, LLC | $291.14 | 2019-2025 | Rayaldee |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $238.00 | 2024-2025 | |
| Akebia Therapeutics INC | $212.85 | 2019-2024 | Auryxia, Vafseo |
| Stryker Corporation | $211.01 | 2021-2023 | Scopis Ent, Audion Et Dilation System |
| Scpharmaceuticals INC. | $151.18 | 2025 | |
| Lilly USA, LLC | $113.36 | 2023-2025 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $111.54 | 2024 | |
| Renalytix Ai, INC. | $104.18 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Apellis Pharmaceuticals, INC. | $95.02 | 2025 | Empaveli |
| Genzyme Corporation | $88.03 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $76.62 | 2022-2025 | Ultomiris |
| Amarin Pharma, INC. | $60.27 | 2020-2021 | |
| Cormedix INC. | $57.91 | 2024-2025 | Defencath, Defencath |
| Novo Nordisk INC | $49.43 | 2024-2025 | Rybelsus, Ozempic |
| Ultragenyx Pharmaceutical INC. | $33.48 | 2020-2023 | Crysvita |
| Strongbridge US INC. | $29.43 | 2019-2020 | |
| Boston Scientific Corporation | $27.94 | 2025 | Infinion 16 |
| Glaxosmithkline, LLC. | $25.25 | 2023 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.34 | 2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $17.85 | 2023 | Xarelto |
| Genentech USA, INC. | $16.99 | 2019 | |
| Shield Therapeutics INC | $13.94 | 2023 | Accrufer |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.